Floatz logo

nk521 cell

Malignant Ascites

Base Therapeutics (Shanghai) Co., Ltd.Cell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

12 Active assets in the Malignant Ascites cohort.

Asset / SponsorPhaseRating
Catumaxomab
Neovii Biotech
Phase 2/3BB
5,5'-DINITROSALICIL
Wuhan YZY Biopharma Co., Ltd.
Phase 3BB
Metformin
University of Chicago
Phase 2B
Molgramostim
Second Affiliated Hospital of Soochow University
Phase 1/2CC
Serplulimab
Second Affiliated Hospital of Soochow University
Phase 1/2CC

View all 14 →

Same molecule, other indications

nk521 cell is also rated in:

hepatocellular carcinomaDormant
C
Indicative ·
36 / 100
View asset →
cancerDormant
C
Indicative ·
33 / 100
View asset →
ovarian cancerDormant
C
Indicative ·
33 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →